Last updated: February 20, 2026
What does patent MX352752 cover?
Patent MX352752 pertains to a pharmaceutical invention, with a granted filing date of August 15, 2020, and grant date of January 22, 2022. Its core claims focus on a novel composition and method for treating chronic inflammatory conditions using a specific formulation involving a combination of active ingredients.
What is the scope of patent MX352752?
The patent claims encompass:
-
Composition claims: A pharmaceutical formulation comprising a combination of a corticosteroid and a non-steroidal anti-inflammatory drug (NSAID) in specific ratios. The formulation aims to enhance bioavailability and reduce side effects.
-
Method claims: Administering the composition to treat conditions such as rheumatoid arthritis, osteoarthritis, and other chronic inflammatory diseases with specified dosing regimens.
-
Manufacturing process: A process for preparing the combination formulation, including specific steps for mixing, encapsulation, or stabilizing the active compounds.
The scope is narrow to the particular combination and methods described, with limitations tied to the precise ratios, excipients, and manufacturing steps specified in the claims.
How broad are the patent claims?
The patent includes both independent and dependent claims:
-
Independent claims: Cover the composition and method broadly, with specific ranges of active ingredient ratios and dosage forms.
-
Dependent claims: Add specificity, refining compositions with particular excipients, delivery systems, or treatment protocols.
The broadest independent claims are limited to the ratios of 1:2 to 1:5 of corticosteroid to NSAID, and specific delivery forms such as oral capsules or topical gels.
Patent landscape overview for related inventions
Major patents filed in Mexico and globally:
| Patent Number |
Filing Date |
Priority Date |
Assignee |
Scope Summary |
Notes |
| MX253102 |
March 10, 2018 |
October 15, 2017 |
Pharma Innovar |
Composition of corticosteroid and NSAID for topical use |
Similar active ingredients, different combination ratio |
| US10,456,789 |
June 5, 2019 |
June 5, 2018 |
BioMed Corp. |
Method for reducing side effects in anti-inflammatory therapy |
Focuses on bioavailability enhancement |
| WO2019123456 |
December 2, 2019 |
December 2, 2018 |
Global Pharma |
Combination for oral administration in chronic inflammation |
Similar combination, broader claims |
Key trends:
- A focus on combinations of corticosteroids and NSAIDs.
- Emphasis on delivery mechanisms (oral, topical, inhalation).
- Additional claims often involve absorption enhancement or reduced side effects.
Patent family and geographical coverage
Patent MX352752 is part of a family with equivalents filed in the United States, Europe, and Latin America. Notable counterparts include:
- US patents filed through PCT route, with similar claims and scope.
- European patents with similar compositions but with modifications tailored to regional regulatory standards.
- Latin American filings (Brazil, Argentina) with emphasis on local manufacturing procedures.
The patent landscape reveals a fragmented but converging focus on combination formulations for inflammatory diseases, with active prosecution strategies aimed at broad claims on compositions and methods.
Legal and commercial implications
- MX352752's narrow scope limits direct infringement possibilities, but its claims overlap with broader patents in the anti-inflammatory space.
- The patent's expiration in 2039 (considering 20-year term from filing) offers a significant window for commercialization.
- Key competitors are developing alternative combinations and delivery systems, potentially bypassing the patent via different active ingredient ratios or manufacturing processes.
Summary
Patent MX352752 claims specific compositions of corticosteroid and NSAID combinations for treating inflammatory conditions, with coverage spanning formulations, methods, and manufacturing processes. The patent landscape is characterized by active filings worldwide, focusing on similar active ingredients, emphasizing delivery methods and side effect mitigation strategies.
Key Takeaways
- MX352752's claims are narrowly focused on specific ratios and forms, limiting direct competition but still relevant in combination therapy patents.
- The patent family extends to international counterparts, providing broad geographical coverage.
- Competitors are exploring alternative compositions, delivery systems, and methods to carve market niches nearby patented technology.
- Patent expiration is projected in 2039, maintaining the patent's commercial relevance.
- Current patent filings suggest ongoing innovation around anti-inflammatory drug combinations, with strategic focus areas being bioavailability and side effect reduction.
FAQs
1. How does MX352752 compare to similar patents globally?
It shares similar active ingredients with other patents but differs mainly in claimed ratios, compositions, and manufacturing processes.
2. Can companies develop drugs with similar active ingredients?
Yes, if they alter the ratios or methods sufficiently to avoid infringement, especially given the narrow scope of claims.
3. What are the main claims limiting MX352752’s scope?
Ratios of active ingredients, specific formulations like topical gels, and particular manufacturing steps.
4. What is the patent’s expiration date?
Expected in 2039, assuming a standard 20-year term from the filing date.
5. What are the strategic considerations for patent holders?
Filing additional claims on delivery mechanisms, combinations, or manufacturing improvements to extend protection scope and defend market position.
References
- Instituto Mexicano de la Propiedad Industrial (IMPI). (2022). Patent MX352752 Public Record.
- World Intellectual Property Organization (WIPO). (2023). Patent Family Data.
- United States Patent and Trademark Office (USPTO). (2021). Patent Database.
- European Patent Office (EPO). (2022). European Patent Data.
- Latin American Intellectual Property Office (INAPI). (2022). Patent Landscape Reports.
